Request Demo
Last update 11 May 2025
Olatorepatide
Last update 11 May 2025
Overview
Basic Info
Drug Type Synthetic peptide |
Synonyms HS 20094, HS-20094, HS20094 |
Target |
Action agonists |
Mechanism GIPR agonists(Gastric inhibitory polypeptide receptor agonists), GLP-1R agonists(Glucagon-like peptide 1 receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Login to view timeline
Structure/Sequence
Sequence Code 651150096
Source: *****
Related
16
Clinical Trials associated with OlatorepatideNCT06839664
A Randomized, Double-blind, Placebo-controlled Phase Ⅲ Clinical Study to Evaluate the Efficacy and Safety of HS-20094 in Overweight and Obese Subjects
CTR20242502
HS-20094不同给药装置之间药代动力学行为比较研究
[Translation] Comparative study on the pharmacokinetic behavior of HS-20094 between different drug delivery devices
CTR20241030
HS-20094不同给药部位之间药代动力学行为比较研究
[Translation] Comparative study on the pharmacokinetic behavior of HS-20094 at different administration sites
100 Clinical Results associated with Olatorepatide
Login to view more data
100 Translational Medicine associated with Olatorepatide
Login to view more data
100 Patents (Medical) associated with Olatorepatide
Login to view more data
100 Deals associated with Olatorepatide
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Obesity | Phase 3 | China | 31 Oct 2024 | |
| Diabetes Mellitus, Type 2 | Phase 2 | China | 30 May 2023 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
NCT06118008 (ADA2024) Manual  | Phase 2 | 54 | HS-20094 5mg | lhwzxpqeza(pcgtcwajnr) = The occurrence of adverse events (AEs) was not dose-dependent in HS-20094. The most common AE included decreased appetite, abdominal distension and vomiting. No severe hypoglycemia was reported. lssbsawjpa (ltszhljdzt ) | Positive | 21 Jun 2024 | |
HS-20094 10mg |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free